Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients receiving Gemcitabine and Irinotecan.

Patient demographics and clinical characteristics.

Alexander M. Menzies (506092)
Lauren E. Haydu (506093)
Matteo S. Carlino (506094)
Mary W. F. Azer (506095)
Peter J. A. Carr (506096)
Richard F. Kefford (506097)
Georgina V. Long (506098)

January 2014

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; AJCC, American Joi...

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohorts, by histology and overall.

Amy P. Abernethy (163142)
Ashwini Arunachalam (4169704)
Thomas Burke (3451004)
Caroline McKay (4169701)
Xiting Cao (4169698)
Rachael Sorg (4169707)
David P. Carbone (830811)

June 2017

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohor...

Percentiles of patients by (a) serum ferritin, (b) TSAT, (c) hemoglobin, and (d) administered EPO for 12 months before and 18 months after study start.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Percentiles of patients by (a) serum ferritin, (b) TSAT, (c) hemoglobin, and (d) administered EPO...

Cohort I: Percent of Targeted Dose (relative to targeted dose at start of treatment) for patients receiving Gemcitabine and Irinotecan.

Shernan G. Holtan (150664)
Preston D. Steen (150669)
Nathan R. Foster (144835)
Charles Erlichman (150676)
Fabiola Medeiros (150680)
Matthew M. Ames (150683)
Stephanie L. Safgren (150686)
David L. Graham (150691)
Robert J. Behrens (150697)
Matthew P. Goetz (150701)

July 2012

Cohort I: Percent of Targeted Dose (relative to targeted dose at start of treatment) for patients...

Plots of the percent change in tumor volume and normalized ADC (ADC) for each of the treatment groups in Study 2.

Stefanie Galbán (296108)
Benjamin Lemasson (325803)
Terence M. Williams (325804)
Fei Li (143236)
Kevin A. Heist (296103)
Timothy D. Johnson (325805)
Judith S. Leopold (325806)
Thomas L. Chenevert (325807)
Theodore S. Lawrence (235458)
Alnawaz Rehemtulla (178)
Tom Mikkelsen (95018)
Eric C. Holland (130584)
Craig J. Galbán (296105)
Brian D. Ross (213312)

February 2013

Presented are treatment groups (A) Control, (B) irradiation (IR), (C) gemcitabine (GEM) and (D) c...

Treatment exposures, number of treatment cycles and median delivered dose of the study drugs.

Gustav J. Ullenhag (716636)
Eva Rossmann (716637)
Maria Liljefors (716638)

April 2015

*NA = not applicable** Administered dose / planned dose according to the protocol per coho...

Detection rate for panel medications in two cohorts.

Timothy P. Ryan (698436)
Ryan D. Morrison (1339743)
Jeffrey J. Sutherland (698432)
Stephen B. Milne (580249)
Kendall A. Ryan (4477093)
J. Scott Daniels (1326204)
Anita Misra-Hebert (4477090)
J. Kevin Hicks (4477099)
Eric Vogan (4477096)
Kathryn Teng (4477102)
Thomas M. Daly (698433)

September 2017

Percent of patients for whom a given medication is detected in Residuals vs. Reconciled Cohorts. ...

Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in each sample.

José M. Quintana (571874)
Ane Antón-Ladislao (5464919)
Nerea González (5464928)
Santiago Lázaro (5464925)
Marisa Baré (501417)
Nerea Fernández-de-Larrea (571872)
Maximino Redondo (87169)
Eduardo Briones (571873)
Antonio Escobar (27986)
Cristina Sarasqueta (22363)
Susana García-Gutierrez (5464922)
Inmaculada Aróstegui (5464916)

June 2018

Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in eac...

Proportion of people receiving chemotherapy and radiotherapy by stage (n = 18513).

Aamir Khakwani (526029)
Anna L. Rich (526030)
Laila J. Tata (139642)
Helen A. Powell (526031)
Rosamund A. Stanley (526032)
David R. Baldwin (526033)
Richard B. Hubbard (526034)

February 2014

Proportion of people receiving chemotherapy and radiotherapy by stage (n = 18513).</p

Cohort demographics for primary and validation cohorts investigated by genome-wide association for the outcome of peak serum creatinine during vancomycin therapy.

Sara L. Van Driest (496623)
Tracy L. McGregor (224807)
Digna R. Velez Edwards (181050)
Ben R. Saville (748286)
Terrie E. Kitchner (748287)
Scott J. Hebbring (748288)
Murray Brilliant (243383)
Hayan Jouni (240910)
Iftikhar J. Kullo (35523)
C. Buddy Creech (748289)
Prince J. Kannankeril (480886)
Susan I. Vear (748290)
Kyle B. Brothers (748291)
Erica A. Bowton (748292)
Christian M. Shaffer (748293)
Neelam Patel (748294)
Jessica T. Delaney (181642)
Yuki Bradford (496693)
Sarah Wilson (669311)
Lana M. Olson (169813)
Dana C. Crawford (102216)
Amy L. Potts (748295)
Richard H. Ho (748296)
Dan M. Roden (181660)
Josh C. Denny (496632)

June 2015

*Median (interquartile range)^N, %.Cohort demographics for primary and validation c...

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation.

Herbert C. Duber (712085)
Emily Dansereau (610260)
Samuel H. Masters (673005)
Jane Achan (145106)
Roy Burstein (673006)
Brendan DeCenso (673007)
Anne Gasasira (232652)
Gloria Ikilezi (673010)
Caroline Kisia (673011)
Felix Masiye (344814)
Pamela Njuguna (357242)
Thomas Odeny (712086)
Emelda Okiro (712087)
D. Allen Roberts (712088)
Emmanuela Gakidou (250582)

March 2015

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation....

90–90 estimates for the total population, at the start and end of Round 2.

Sian Floyd (239400)
Helen Ayles (42807)
Albertus Schaap (372843)
Kwame Shanaube (353723)
David MacLeod (466263)
Mwelwa Phiri (5620625)
Sam Griffith (438433)
Peter Bock (361592)
Nulda Beyers (305944)
Sarah Fidler (76851)
Richard Hayes (32740)

August 2018

Dark blue bars show the estimated percentage of HIV+ individuals who knew their HIV+ status (first 9...

Patients baseline characteristics and number of patients per treatment arm in phase II.

Gustav J. Ullenhag (716636)
Fariba Mozaffari (825548)
Mats Broberg (3666814)
Håkan Mellstedt (3666817)
Maria Liljefors (716638)

January 2017

Patients baseline characteristics and number of patients per treatment arm in phase II.</p

Percentage of patients virally suppressed stratified into different groups of adherence for the 2,086 patients participating in the Health Questionnaire Study Cohort, treated for more than six months.

Gaetano Marrone (239053)
Åsa Mellgren (2838422)
Lars E. Eriksson (490680)
Veronica Svedhem (2838425)

June 2016

Percentage of patients virally suppressed stratified into different groups of adherence for the 2...

Phase I Study of Irinotecan and Gemcitabine in Previously Untreated Patients with Advanced Non-small Cell Lung Cancer

Hiroshi Takatani
Hiroshi Soda
Yoichi Nakamura
Akitoshi Kinoshita
Masaaki Fukuda
Seiji Nagashima
Minoru Fukuda
Yoshifumi Soejima
Hirofumi Nakano
Mikio Oka
Shigeru Kohno
The Nagasaki

January 2006

Background: Irinotecan and gemcitabine are effective against non-small cell lung cancer. We conducte...

Patient demographics and clinical characteristics.

Alexander M. Menzies (506092)
Lauren E. Haydu (506093)
Matteo S. Carlino (506094)
Mary W. F. Azer (506095)
Peter J. A. Carr (506096)
Richard F. Kefford (506097)
Georgina V. Long (506098)

January 2014

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; AJCC, American Joi...

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohorts, by histology and overall.

Amy P. Abernethy (163142)
Ashwini Arunachalam (4169704)
Thomas Burke (3451004)
Caroline McKay (4169701)
Xiting Cao (4169698)
Rachael Sorg (4169707)
David P. Carbone (830811)

June 2017

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohor...

Percentiles of patients by (a) serum ferritin, (b) TSAT, (c) hemoglobin, and (d) administered EPO for 12 months before and 18 months after study start.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Percentiles of patients by (a) serum ferritin, (b) TSAT, (c) hemoglobin, and (d) administered EPO...

Cohort I: Percent of Targeted Dose (relative to targeted dose at start of treatment) for patients receiving Gemcitabine and Irinotecan.

Shernan G. Holtan (150664)
Preston D. Steen (150669)
Nathan R. Foster (144835)
Charles Erlichman (150676)
Fabiola Medeiros (150680)
Matthew M. Ames (150683)
Stephanie L. Safgren (150686)
David L. Graham (150691)
Robert J. Behrens (150697)
Matthew P. Goetz (150701)

July 2012

Cohort I: Percent of Targeted Dose (relative to targeted dose at start of treatment) for patients...

Plots of the percent change in tumor volume and normalized ADC (ADC) for each of the treatment groups in Study 2.

Stefanie Galbán (296108)
Benjamin Lemasson (325803)
Terence M. Williams (325804)
Fei Li (143236)
Kevin A. Heist (296103)
Timothy D. Johnson (325805)
Judith S. Leopold (325806)
Thomas L. Chenevert (325807)
Theodore S. Lawrence (235458)
Alnawaz Rehemtulla (178)
Tom Mikkelsen (95018)
Eric C. Holland (130584)
Craig J. Galbán (296105)
Brian D. Ross (213312)

February 2013

Presented are treatment groups (A) Control, (B) irradiation (IR), (C) gemcitabine (GEM) and (D) c...

Treatment exposures, number of treatment cycles and median delivered dose of the study drugs.

Gustav J. Ullenhag (716636)
Eva Rossmann (716637)
Maria Liljefors (716638)

April 2015

*NA = not applicable** Administered dose / planned dose according to the protocol per coho...

Detection rate for panel medications in two cohorts.

Timothy P. Ryan (698436)
Ryan D. Morrison (1339743)
Jeffrey J. Sutherland (698432)
Stephen B. Milne (580249)
Kendall A. Ryan (4477093)
J. Scott Daniels (1326204)
Anita Misra-Hebert (4477090)
J. Kevin Hicks (4477099)
Eric Vogan (4477096)
Kathryn Teng (4477102)
Thomas M. Daly (698433)

September 2017

Percent of patients for whom a given medication is detected in Residuals vs. Reconciled Cohorts. ...

Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in each sample.

José M. Quintana (571874)
Ane Antón-Ladislao (5464919)
Nerea González (5464928)
Santiago Lázaro (5464925)
Marisa Baré (501417)
Nerea Fernández-de-Larrea (571872)
Maximino Redondo (87169)
Eduardo Briones (571873)
Antonio Escobar (27986)
Cristina Sarasqueta (22363)
Susana García-Gutierrez (5464922)
Inmaculada Aróstegui (5464916)

June 2018

Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in eac...

Proportion of people receiving chemotherapy and radiotherapy by stage (n = 18513).

Aamir Khakwani (526029)
Anna L. Rich (526030)
Laila J. Tata (139642)
Helen A. Powell (526031)
Rosamund A. Stanley (526032)
David R. Baldwin (526033)
Richard B. Hubbard (526034)

February 2014

Proportion of people receiving chemotherapy and radiotherapy by stage (n = 18513).</p

Cohort demographics for primary and validation cohorts investigated by genome-wide association for the outcome of peak serum creatinine during vancomycin therapy.

Sara L. Van Driest (496623)
Tracy L. McGregor (224807)
Digna R. Velez Edwards (181050)
Ben R. Saville (748286)
Terrie E. Kitchner (748287)
Scott J. Hebbring (748288)
Murray Brilliant (243383)
Hayan Jouni (240910)
Iftikhar J. Kullo (35523)
C. Buddy Creech (748289)
Prince J. Kannankeril (480886)
Susan I. Vear (748290)
Kyle B. Brothers (748291)
Erica A. Bowton (748292)
Christian M. Shaffer (748293)
Neelam Patel (748294)
Jessica T. Delaney (181642)
Yuki Bradford (496693)
Sarah Wilson (669311)
Lana M. Olson (169813)
Dana C. Crawford (102216)
Amy L. Potts (748295)
Richard H. Ho (748296)
Dan M. Roden (181660)
Josh C. Denny (496632)

June 2015

*Median (interquartile range)^N, %.Cohort demographics for primary and validation c...

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation.

Herbert C. Duber (712085)
Emily Dansereau (610260)
Samuel H. Masters (673005)
Jane Achan (145106)
Roy Burstein (673006)
Brendan DeCenso (673007)
Anne Gasasira (232652)
Gloria Ikilezi (673010)
Caroline Kisia (673011)
Felix Masiye (344814)
Pamela Njuguna (357242)
Thomas Odeny (712086)
Emelda Okiro (712087)
D. Allen Roberts (712088)
Emmanuela Gakidou (250582)

March 2015

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation....

90–90 estimates for the total population, at the start and end of Round 2.

Sian Floyd (239400)
Helen Ayles (42807)
Albertus Schaap (372843)
Kwame Shanaube (353723)
David MacLeod (466263)
Mwelwa Phiri (5620625)
Sam Griffith (438433)
Peter Bock (361592)
Nulda Beyers (305944)
Sarah Fidler (76851)
Richard Hayes (32740)

August 2018

Dark blue bars show the estimated percentage of HIV+ individuals who knew their HIV+ status (first 9...

Patients baseline characteristics and number of patients per treatment arm in phase II.

Gustav J. Ullenhag (716636)
Fariba Mozaffari (825548)
Mats Broberg (3666814)
Håkan Mellstedt (3666817)
Maria Liljefors (716638)

January 2017

Patients baseline characteristics and number of patients per treatment arm in phase II.</p

Percentage of patients virally suppressed stratified into different groups of adherence for the 2,086 patients participating in the Health Questionnaire Study Cohort, treated for more than six months.

Gaetano Marrone (239053)
Åsa Mellgren (2838422)
Lars E. Eriksson (490680)
Veronica Svedhem (2838425)

June 2016

Percentage of patients virally suppressed stratified into different groups of adherence for the 2...

Phase I Study of Irinotecan and Gemcitabine in Previously Untreated Patients with Advanced Non-small Cell Lung Cancer

Hiroshi Takatani
Hiroshi Soda
Yoichi Nakamura
Akitoshi Kinoshita
Masaaki Fukuda
Seiji Nagashima
Minoru Fukuda
Yoshifumi Soejima
Hirofumi Nakano
Mikio Oka
Shigeru Kohno
The Nagasaki

January 2006

Background: Irinotecan and gemcitabine are effective against non-small cell lung cancer. We conducte...

Patient demographics and clinical characteristics.

Alexander M. Menzies (506092)
Lauren E. Haydu (506093)
Matteo S. Carlino (506094)
Mary W. F. Azer (506095)
Peter J. A. Carr (506096)
Richard F. Kefford (506097)
Georgina V. Long (506098)

January 2014

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; AJCC, American Joi...

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohorts, by histology and overall.

Amy P. Abernethy (163142)
Ashwini Arunachalam (4169704)
Thomas Burke (3451004)
Caroline McKay (4169701)
Xiting Cao (4169698)
Rachael Sorg (4169707)
David P. Carbone (830811)

June 2017

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohor...

Percentiles of patients by (a) serum ferritin, (b) TSAT, (c) hemoglobin, and (d) administered EPO for 12 months before and 18 months after study start.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Percentiles of patients by (a) serum ferritin, (b) TSAT, (c) hemoglobin, and (d) administered EPO...

Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients receiving Gemcitabine and Irinotecan.

Abstract

Extracted data

Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients receiving Gemcitabine and Irinotecan.

Abstract

Extracted data

Topics

Related items

Topics

Related items